<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284712</url>
  </required_header>
  <id_info>
    <org_study_id>2009/16</org_study_id>
    <secondary_id>2009-A00395-52</secondary_id>
    <nct_id>NCT01284712</nct_id>
  </id_info>
  <brief_title>Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Natural Killer cells (NK) are pivotal cells of innate immunity, that sense defective&#xD;
      expression of HLA class I molecules and are complementary to specific cytotoxic T&#xD;
      lymphocytes. A defect in NK cell cytotoxicity has been described in some hematopoietic&#xD;
      malignancies such as acute myeloid leukemia, multiple myeloma, myelodysplastic syndroms. This&#xD;
      defect is at least partially linked to a decreased or absent expression of some activating NK&#xD;
      cell molecules, more particularly the so-called Natural Cytotoxicity Receptors (NCRs) NKp30,&#xD;
      NKp44 and NKp46. Some old publications have demonstrated defective NK cytotoxicity in&#xD;
      myeloproliferative syndroms (chronic myeloid leukemia, primary thrombocytosis, polycythemia&#xD;
      vera). The investigators more particularly focused their attention on polycythemia vera&#xD;
      (Vaquez's disease), a myeloproliferative disease characterized by the recently describet&#xD;
      mutation V617F of the JAK2 tyrosine kinase. The investigators will precise the mechanisms&#xD;
      leading to this cytotoxicity defect, the investigators also will evaluate the implication of&#xD;
      V617F mutation on NK physiology, and will study the interactions between NK cells and&#xD;
      hematopoietic progenitors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To describe immunologic anomalies in polycythemia vera</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Polycythemia Vera</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood sample coming from therapeutic bleeding in hospital</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        VAQUEZ'S DISEASE&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Polycythemia vera&#xD;
&#xD;
          -  Treatment by therapeutic bleedings&#xD;
&#xD;
          -  No cytotoxic treatment during the previous six months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No Polycythemia vera&#xD;
&#xD;
          -  No treatment by therapeutic bleedings&#xD;
&#xD;
          -  Cytotoxic treatment during the previous six months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regis Costello</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment by bleedings</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

